Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efinopegdutide - Hanmi Pharmaceutical

Next Previous
Drug Profile

Efinopegdutide - Hanmi Pharmaceutical

Alternative Names: GLP-1/glucagon-agonist; Glucagon-like-peptides/glucagon; Glucagon/GLP-1-agonist; HM-12525A; JNJ 5111; JNJ-64565111; LAPS GLP/GCG; LAPS-GCG/GLP-1; LAPS-GLP-1/GCG; LAPS-GLP/GCG agonist; LAPS-GLP/Glucagon; LAPS-OXM; MK-6024; Oxyntomodulin immunoglobulin conjugate

Latest Information Update: 05 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Janssen Pharmaceuticals; Merck & Co
  • Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Immunoglobulin Fc fragments; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cirrhosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 05 Aug 2026 Hanmi Pharmaceuticals has patent protection for conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof in the US and multiple locations in the World
  • 04 Aug 2026 Hanmi Pharmaceuticals plans a phase III trial for Non-alcoholic steatohepatitis in 2027
  • 29 Dec 2025 Merck Sharp & Dohme completes a phase II trial in Non-alcoholic steatohepatitis in The US, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Hong-Kong, Hungary, Israel, Italy, Japan, Mexico, Peru, Portugal, Puerto Rico, Singapore, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey and the United Kingdom (SC) (NCT05877547)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top